Health-related quality of life outcomes in children and adolescents with ADHD treated with lisdexamfetamine dimesylate
Tobias Banaschewski(Heidelberg University), David Coghill(The University of Melbourne), Alessandro Zuddas(University of Cagliari), César A. Soutullo(The University of Texas Health Science Center), Mats Johnson(Sahlgrenska University Hospital), Ralph Bloomfield(AstraZeneca (United Kingdom)), P. Hodgkins(Takeda (United States)), Liza Squires
Cited by 1
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Computerized Training of Working Memory in Children With ADHD-A Randomized, Controlled Trial
|Journal of the American Academy of Child & Adolescent Psychiatry|2005|2k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders
|Cell|2019|1.5k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k